Enterprise Value
-41.05M
Cash
57.63M
Avg Qtr Burn
-5.712M
Short % of Float
0.73%
Insider Ownership
17.22%
Institutional Own.
9.34%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
LSTA12 (HONEDRA®) Details Critical limb ischemia | Phase 3 Update | |
LSTA1 Details Pancreatic cancer, Cancer | Phase 2b Data readout | |
LSTA1 + Standard of care Details Cancer, Solid tumor/s, Esophageal cancer, Head and neck cancer, Cholangiocarcinoma | Phase 2a Data readout | |
LSTA1 + temozolomide Details Cancer, Glioblastoma, Glioma | Phase 2a Data readout | |
LSTA1 + nivolumab/FOLFIRINOX, Details Cancer, Gastroesophageal adenocarcinomas | Phase 1/2 Data readout | |
LSTA1 + Durvalumab/gemcitabine/nab-paclitaxel Details Pancreatic cancer, Cancer | Phase 1/2 Data readout | |
LSTA1 + FOLFIRINOX (neoadjuvant) + panitumumab Details Pancreatic cancer, Cancer, Colorectal cancer | Phase 1/2 Data readout | |
LSTA1 + gemcitabine/nab-paclitaxel Details Pancreatic cancer, Cancer | Phase 1/2 Data readout | |
OLOGO (CLBS14) Details Angina | Failed Discontinued | |
LSTA201 (CLBS201) Details Chronic kidney disease | Failed Discontinued | |
XOWNA (CLBS16) Details Coronary Microvascular Dysfunction | Failed Discontinued |